Nicolas Penel
Overview
Explore the profile of Nicolas Penel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
324
Citations
6177
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Blay J, Devin Q, Duffaud F, Toulmonde M, Firmin N, Collard O, et al.
Lancet Oncol
. 2024 Aug;
25(9):1163-1175.
PMID: 39127063
Background: The long-term impact of tyrosine kinase inhibitor (TKI) discontinuation on resistance and survival in patients with advanced gastrointestinal stromal tumours (GIST) is unclear. We report the exploratory long-term outcomes...
12.
Blay J, Penel N, Toulmonde M, Valentin T, Chaigneau L, Rios M, et al.
Eur J Cancer
. 2024 Jul;
208:114228.
PMID: 39018632
Rationale: We report a phase II trial (OSAD93) testing CDDP with ifosfamide (IFO), without doxorubicin in neoadjuvant phase, in adult osteosarcoma with a 25 years follow-up. Patients And Methods: This...
13.
Kasper B, Baldini E, Bonvalot S, Callegaro D, Cardona K, Colombo C, et al.
JAMA Oncol
. 2024 Jun;
10(8):1121-1128.
PMID: 38900421
Importance: Desmoid tumor (DT) is a rare and locally aggressive monoclonal, fibroblastic proliferation characterized by a variable and often unpredictable clinical course. Previously, surgery was the standard primary treatment modality;...
14.
Penel N, Hudry D, Cren P
Bull Cancer
. 2024 Jun;
111(9):799-801.
PMID: 38876893
No abstract available.
15.
Naffrichoux J, Poupin P, Pouillot W, Linassier C, Rioux-Leclercq N, De Vries-Brilland M, et al.
Eur J Cancer
. 2024 May;
205:114121.
PMID: 38749111
Introduction: Papillary renal cell carcinoma (pRCC) is a rare and aggressive cancer with no specifically established therapeutic strategy in the metastatic setting. Combinations of tyrosine kinase and immune checkpoint inhibitors...
16.
Laurent E, Ducrocq C, Cren P, Boutaa K, Crie D, Penel N
Bull Cancer
. 2024 Mar;
111(5):505-512.
PMID: 38553287
Introduction: Given the current global cancer epidemic across the world, the need for healthcare professionals in this field is crucial. Little is known about the factors that drive medical students...
17.
De Metz C, Hennart B, Aymes E, Cren P, Martignene N, Penel N, et al.
Cancer Med
. 2024 Mar;
13(6):e7066.
PMID: 38523525
Introduction: In April 2019, French authorities mandated dihydropyrimidine dehydrogenase (DPD) screening, specifically testing uracilemia, to mitigate the risk of toxicity associated with fluoropyrimidine-based chemotherapy. However, this subject is still of...
18.
Coquan E, Penel N, Lequesne J, Leman R, Lavaud P, Neviere Z, et al.
Ther Adv Urol
. 2024 Mar;
16:17562872241229876.
PMID: 38425504
Introduction: DNA damage repair genes are altered in 20-35% of metastatic castration-resistant prostate cancer (mCRPC). Poly-ADP (Adénosine Diphosphate)-ribose polymerase inhibitors (PARPi) showed significant activity for these selected tumors, especially with...
19.
Huchet N, Penel N, Bonvalot S, Thariat J, Ducimetiere F, Giraud A, et al.
Ther Adv Med Oncol
. 2024 Jan;
16:17588359231220999.
PMID: 38249328
Background: Missing covariates are common in observational research and can lead to bias and loss of statistical power. Limited data regarding prognostic factors of survival outcomes of sarcomas in irradiated...
20.
Penel N, Mailliez A, Pannier D, Ducrocq C
Bull Cancer
. 2024 Jan;
111(2):222-227.
PMID: 38199834
Information overload, informational stress and its deleterious consequences constitute a subject of growing interest in the way of work. This is quite well documented among anesthesiologists. Studies have also been...